版本:
中国

BRIEF-U.S. FDA approves Merck's Keytruda chemo combo for lung cancer

May 10 Merck & Co Inc

* Fda approves Merck's Keytruda® (pembrolizumab) as first-line combination therapy with pemetrexed and carboplatin for patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-l1 expression

* Merck & Co Inc - Under FDA's accelerated approval regulations, this indication is approved based on tumor response rate and progression-free survival Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐